Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus ultra-hyper-fractionated radiotherapy vs temozolomide alone as maintenance in glioblastoma (pilot)
2021-003275-34Phase 2Terminated
- Sponsor
- IRCCS-A.O.U. SAN MARTINO-IST
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by IRCCS-A.O.U. SAN MARTINO-IST. Primary endpoint: Overall survival. Started Oct 2021; status: terminated.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2021-003275-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003275-34.